via Genetic Engineering and Biotechnology News
LumosVar — a name inspired by Harry Potter — could help physicians provide genomic-based treatments for their patients
By conjuring the spell “Lumos!” wizards in the mythical world of Harry Potter could light up the tip of their magic wands and illuminate their surroundings. So, too, does LumosVar, a computer program developed by the Translational Genomics Research Institute (TGen), “light up” cancer-causing genetic Var-ients, or mutations, illuminating how physicians might best treat their patients.
A study published today in the scientific journal Frontiers in Oncology describes how researchers at TGen, an affiliate of City of Hope, developed LumosVar to create a tool that can accurately identify cancer-causing mutations from patient tumor samples.
In the case of archived samples from patients for which treatment outcome results are known, these represent a treasure trove of information that could accelerate research by investigators and physicians in predicting responses of future patients to particular treatments.
“There are many open questions in precision oncology that can only be answered by collecting large amounts of patient genomic data linked to treatment response and clinical outcomes,” said Dr. Rebecca Halperin, a Research Assistant Professor in TGen’s Quantitative Medicine and Systems Biology Program.
“The approach we outline in this study should enable researchers to use archival samples more effectively. Accurately calling, or identifying, somatic variants — those DNA changes specific to a patient’s cancer — are the first step in any analysis,” said Dr. Halperin, the study’s lead author.
However, archived tumor samples are frequently not accompanied by the patients’ normal — or germline — genetic information, making it difficult to distinguish the patient’s normal DNA variants to their mutated and cancerous DNA changes.
LumosVar is a precise enough tool that it not only can detect the cancerous DNA from a patient sample, but it also can differentiate the adjacent normal DNA that may surround the tumor in the sample. Comparing the patient’s normal DNA from a suspected cancer-causing mutation is critical to eliminating benign, non-cancerous variants in the sample — “false positives” — and ensuring that the tissue sample analysis is as accurate as possible.
A high level of accuracy is needed for physicians to use this information in precision medicine, determining what treatment each individual patient should receive.
“The sequencing of DNA from tissue adjacent to the tumor could help identify somatic, or cancer-causing, mutations when another source of normal tissue is not available,” said Dr. Sara Byron, Research Assistant Professor in TGen’s Integrated Cancer Genomics Division, and also the study’s senior author.
Learn more: AS IF BY MAGIC: TGEN DEVELOPS PROGRAM THAT LIGHTS UP CANCER-CAUSING MUTATIONS
The Latest on: Genomic-based treatments
via Google News
The Latest on: Genomic-based treatments
- Yale's cellular spray paint highlights "dark matter" of the genomeon August 1, 2022 at 7:16 pm
While science continues to identify and unravel the role of the thousands of proteins in the human body, many of them are too small to be picked up with current techniques. These ghost microproteins ...
- New lupus treatments offer a better chance for remissionon August 1, 2022 at 6:50 am
One of the most difficult things about lupus, a chronic autoimmune disease, is that people who have it don't always realize it—they know something's not right, but they're not sure what. They may feel ...
- Intellia Therapeutics Is Pushing CRISPR-Based Therapy Forward, Slowly But Surelyon July 29, 2022 at 10:31 pm
Intellia’s recent data from its Regeneron collaboration for CRISPR-based NTLA-2001 shows a durable response to the lead in vivo genome editing candidate.
- Understanding the genetic testing-related information needs of ovarian cancer patientson July 29, 2022 at 3:51 pm
JMIR Publications recently published "Understanding the Information Needs of Patients With Ovarian Cancer Regarding Genetic Testing to Inform Intervention Design: Interview Study" in JMIR Cancer, ...
- Scientists Discover Genetic Clues Related to Treating Macular Degenerationon July 28, 2022 at 12:30 pm
Better treatments for an eye condition that can cause blindness are a major step closer after scientists discovered genetic clues that show who has it. Researchers in Australia have unearthed genetic ...
- Gut disorders and Alzheimer's: Scientists find genetic linkon July 28, 2022 at 7:26 am
A new study suggests that gut disorders may indicate a greater risk of developing Alzheimer's disease, strengthening theories around the gut-brain axis.
- People Respond Differently to Psychedelic Drugs — Genetics Could Be One Reasonon July 28, 2022 at 5:14 am
Studies have shown around one-third of people with mental health conditions like depression don't respond to psychedelic-assisted treatment. Scientists aren't entirely sure why, but new research ...
- Molecular Drivers of Multiple Myeloma and Treatment Resistance Identifiedon July 28, 2022 at 5:00 am
Results provide new insights into the genetic basis of relapsed multiple myeloma resistance to commonly used treatments.
- Genetic variations in one serotonin receptor could be the reason behind psychedelic treatment disparityon July 27, 2022 at 8:10 pm
When all else fails, some patients trying to overcome alcoholism, severe depression or anxiety, and even cluster headaches, turn to psychedelic drugs, which clinical research has shown can help treat ...
- Exclusive: Mable raises $3M for DNA-based migraine treatmenton July 27, 2022 at 5:05 am
Context: Other consumer-facing digital health companies offer personalized migraine treatments without genetic testing, while several genomics companies offer migraine-focused genetic testing without ...
via Bing News